Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Lowered to Strong Sell Rating by Zacks Research

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Tuesday,Zacks.com reports.

BAYRY has been the topic of a number of other research reports. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. DZ Bank downgraded shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a research report on Wednesday, February 18th. Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Finally, JPMorgan Chase & Co. raised shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Price Performance

Shares of OTCMKTS:BAYRY opened at $10.98 on Tuesday. The firm has a market cap of $43.15 billion, a price-to-earnings ratio of -9.89 and a beta of 0.69. Bayer Aktiengesellschaft has a 1 year low of $5.30 and a 1 year high of $14.85. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. The business has a fifty day simple moving average of $12.43 and a 200 day simple moving average of $10.18.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its earnings results on Wednesday, March 4th. The company reported $0.18 EPS for the quarter, meeting analysts’ consensus estimates of $0.18. Bayer Aktiengesellschaft had a positive return on equity of 15.35% and a negative net margin of 8.51%.The firm had revenue of $13.24 billion for the quarter, compared to the consensus estimate of $13.08 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. As a group, sell-side analysts predict that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.